Valuation: Gyre Therapeutics, Inc.

Market Cap 714M 619M 580M 530M 1B 67.97B 1.01B 6.78B 2.66B 33.96B 2.68B 2.62B 113B P/E 2026 *
-22.1x
P/E 2027 * -55.7x
Enterprise Value 714M 619M 580M 530M 1B 67.97B 1.01B 6.78B 2.66B 33.96B 2.68B 2.62B 113B EV / Sales 2026 *
6.97x
EV / Sales 2027 * 5.46x
Free-Float
13.67%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week+5.85%
Current month+6.96%
1 month-15.29%
3 months-23.51%
6 months-21.95%
Current year-12.89%
1 week 5.8
Extreme 5.8
6.51
1 month 5.62
Extreme 5.62
6.98
Current year 5.44
Extreme 5.44
9.14
1 year 5.44
Extreme 5.44
9.42
3 years 5.44
Extreme 5.44
30.4
5 years 5.44
Extreme 5.44
30.4
10 years 5.44
Extreme 5.44
30.4
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Free

Director

40,000 0.0359%
6/10/26 Free

Director

40,000 0.0412%
5/14/26 Issuer sale

Chairman

-250,000 0.2577%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+5.85%-12.39% - 695M
+0.93%-0.63%+3.89%+14.93% 48.57B
+0.26%+2.93%+439.43%+533.80% 41.95B
-1.53%-2.25%+30.95%+7.15% 38.85B
+0.69%+2.40%+10.48%+63.05% 37.24B
+2.47%+2.63%+14.71%+48.37% 30.67B
-0.47%+1.16%+35.93%+126.09% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.87%+8.17%+18.60% 13.97B
-1.43%-2.63%+3.70%-36.38% 12.62B
Average +0.42%+1.18%+59.43%+96.95% 25.71B
Weighted average by Cap. +0.44%+0.25%+88.84%+121.09%

Financials

2026 *2027 *
Net sales 102M 88.78M 83.13M 76.04M 144M 9.74B 145M 973M 382M 4.87B 384M 376M 16.21B 131M 113M 106M 97.19M 183M 12.46B 186M 1.24B 488M 6.22B 491M 480M 20.71B
Net income -19.15M -16.62M -15.56M -14.23M -26.87M -1.82B -27.22M -182M -71.44M -911M -71.9M -70.34M -3.03B -15.7M -13.62M -12.76M -11.67M -22.03M -1.5B -22.32M -149M -58.57M -747M -58.95M -57.67M -2.49B
Net Debt - -
Logo Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.
Employees
625
Date Price Change Volume
26-08-06 US$6.400 +2.73% 49,085
26-08-05 US$6.230 +1.30% 35,251
26-08-04 US$6.150 +0.65% 63,211
26-08-03 US$6.110 +6.26% 53,655
26-07-31 US$5.750 -1.03% 48,381
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.400USD
Average target price
18.67USD
Spread / Average Target
+191.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GYRE Stock